Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
Arbutus Biopharma (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a functional cure for chronic hepatitis B virus (cHBV) infection, has announced its participation in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference. The company will present a fireside chat on October 8, 2024, at 1:30 pm ET.
Investors and interested parties can access the live webcast of the fireside chat through the Arbutus website at https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the company's website for a time after the event. Arbutus will also host one-on-one meetings during the conference.
Arbutus Biopharma (Nasdaq: ABUS), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di una cura funzionale per l'infezione da virus dell'epatite B cronica (cHBV), ha annunciato la sua partecipazione alla 5ª Conferenza Virtuale Annuale sulle Epatiti Virali di H.C. Wainwright. L'azienda presenterà una chiacchierata al coinoloveso (8 ottobre 2024, alle 1:30 pm ET).
Gli investitori e le parti interessate possono accedere alla trasmissione in diretta della chiacchierata sul sito web di Arbutus all'indirizzo https://investor.arbutusbio.com/events-presentations. Una registrazione archiviata della trasmissione sarà disponibile sul sito dell'azienda per un certo periodo dopo l'evento. Arbutus organizzerà anche incontri one-to-one durante la conferenza.
Arbutus Biopharma (Nasdaq: ABUS), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de una cura funcional para la infección por el virus de la hepatitis B crónica (cHBV), ha anunciado su participación en la 5ª Conferencia Virtual Anual sobre Hepatitis Viral de H.C. Wainwright. La empresa presentará un chat de fogata el 8 de octubre de 2024, a la 1:30 pm ET.
Los inversores y partes interesadas pueden acceder a la transmisión en vivo del chat de fogata a través del sitio web de Arbutus en https://investor.arbutusbio.com/events-presentations. Se dispondrá de una repetición archivada de la transmisión en el sitio web de la empresa por un tiempo después del evento. Arbutus también organizará reuniones uno a uno durante la conferencia.
Arbutus Biopharma (Nasdaq: ABUS)는 만성 간염 B 바이러스(cHBV) 감염을 위한 기능적 치료법 개발에 집중하는 임상 단계의 생명공학 회사입니다. 이 회사는 H.C. Wainwright 제5회 연간 바이러스 간염 가상 회의에 참여할 것이라고 발표했습니다. 회사는 2024년 10월 8일 오후 1:30 ET에 난로 옆 대화를 발표할 예정입니다.
투자자 및 관심 있는 당사자는 Arbutus 웹사이트(https://investor.arbutusbio.com/events-presentations)를 통해 난로 옆 대화의 실시간 웹캐스트에 접근할 수 있습니다. 사건 이후 일정 기간 동안 회사 웹사이트에서 웹캐스트의 아카이브 재생이 제공됩니다. Arbutus는 회의 동안 1:1 미팅도 주최할 예정입니다.
Arbutus Biopharma (Nasdaq: ABUS), une entreprise biopharmaceutique en phase clinique axée sur le développement d'un traitement fonctionnel pour l'infection chronique par le virus de l'hépatite B (cHBV), a annoncé sa participation à la 5ème Conférence Virtuelle Annuelle sur les Hépatites Virales de H.C. Wainwright. L'entreprise présentera une discussion autour du feu le 8 octobre 2024 à 13h30 ET.
Les investisseurs et parties intéressées peuvent accéder à la diffusion en direct de la discussion autour du feu via le site Web d'Arbutus à l'adresse https://investor.arbutusbio.com/events-presentations. Un replay archivé de la diffusion sera disponible sur le site de l'entreprise pendant un certain temps après l'événement. Arbutus organisera également des réunions individuelles durant la conférence.
Arbutus Biopharma (Nasdaq: ABUS), ein klinisches biopharmazeutisches Unternehmen, das sich auf die Entwicklung einer funktionalen Heilung für eine chronische Hepatitis B-Virusinfektion (cHBV) konzentriert, hat seine Teilnahme an der 5. jährlichen virtuellen Konferenz zu Virushepatitis von H.C. Wainwright bekannt gegeben. Das Unternehmen wird am 8. Oktober 2024 um 13:30 Uhr ET ein Feuerseitengespräch präsentieren.
Investoren und interessierte Parteien können über die Arbutus-Website auf den Live-Webcast des Feuerseitengesprächs zugreifen unter https://investor.arbutusbio.com/events-presentations. Eine aufgezeichnete Wiederholung des Webcasts wird nach der Veranstaltung für eine Zeit auf der Unternehmenswebsite verfügbar sein. Arbutus wird auch Einzelgespräche während der Konferenz veranstalten.
- None.
- None.
WARMINSTER, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Company will present at and host one-on-one meetings at the following upcoming investor conference:
H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference: Fireside Chat on October 8, 2024 at 1:30 pm ET
To access the live webcast of the fireside chat, please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visit www.arbutusbio.com.
Contact Information
Investors and Media
Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com
FAQ
When is Arbutus Biopharma (ABUS) presenting at the H.C. Wainwright Viral Hepatitis Conference?
How can I access the webcast of Arbutus Biopharma's (ABUS) presentation?
What is the main focus of Arbutus Biopharma (ABUS)?
Will Arbutus Biopharma (ABUS) be hosting one-on-one meetings at the conference?
